Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05570110
Other study ID # MNS_02.1
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date September 23, 2022
Est. completion date March 2025

Study information

Verified date April 2024
Source Philipps University Marburg Medical Center
Contact Ulrich Schu, MD
Phone +49 6421 5865200
Email schu@uni-marburg.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Many different forms of depression exist. It is difficult to predict to what treatment a given patient with depression responds. Studies demonstrate that biomarkers can help to distinguish different forms of depression. Simple markers, like aldosterone/cortisol in body fluids, blood pressure and inflammation markers , have been identified as predictors of therapy resistance in depression. Enoxolone is a molecule derived from the licorice plant and has demonstrated an effect on these biomarkers, which may imply an improved response. The current randomized placebo controlled study is assessing whether the presence of markers of therapy resistance can predict a preferential effect of enoxolone vs. placebo on clinical outcome. Secondarily, it is tested whether these markers change differentially in the treatment groups. Finally, the relationship between the change of the markers and clinical change will be assessed.


Description:

The objective of the study is 1. to confirm patient characteristics, which are related to lesser responsivity to antidepressant treatment and 2. to explore the utility of the 11 beta hydroxysteroid-dehydrogenase type 2 (11betaHSD2) inhibitor enoxolone to reverse these markers of refractoriness and, potentially, improve clinical outcome. A broad spectrum of patients is recruited in order to provide the opportunity to compare those with relevant markers of refractoriness vs. those without. The identified markers are related to the activity of aldosterone, which appears to affect specific CNS areas, which are involved in mood and autonomic regulation. One area of particular relevance is the pontine nucleus of the solitary tract (NTS). Potential primary triggers for an increased aldosterone release under stressful conditions are related to low blood pressure, electrolyte alterations and a dysfunction of the peripheral mineralocorticoid receptor (MR). The resultant aldosterone release evokes activity at the NTS, which may lead to depression and anxiety. Enoxolone leads to an activation primarily of the peripheral MR by reducing the activity of the 11betaHSD2, therefore allowing cortisol access to the MR and, as a consequence, suppress the release of renin, angiotensin and aldosterone. In addition, it can increase blood pressure slightly. 1. A set of potentially predictive markers for therapy response of enoxolone vs. placebo will be studied, based on this mechanistic pathway, in detail: For the primary analysis subjects are grouped into those with higher vs. lower systolic blood pressure values, as determined by the median systolic blood pressure value at baseline. For the secondary analysis the ratio of urine aldosterone/cortisol, as collected over night will be used as a differentiating parameter. Split at the median defines the groups. Exploratory parameters for a split are the following: 1. sleep duration 2. heart rate variability 3. salt taste sensitivity and salt preference 4. inflammation markers, in particular C-reactive protein in plasma. 5. Optional: volumes of lateral ventricles, corpus callosum and choroid plexi. 6. Optional: white matter integrity, as measured by diffusion tensor imaging 2. Markers of target engagement: 1. Effect of enoxolone vs. placebo on systolic blood pressure. 2. Effect of enoxolone vs. placebo on urine aldosterone/cortisol concentration. 3. Effect of enoxolone vs. placebo on plasma sodium/potassium concentration ratio. 3. The relationship between changes in hormone concentrations and markers of CNS activation of MR, i.e. functional CNS target engagement. These are: 1. Heart rate variability and heart rate 2. Systolic blood pressure at rest and nocturnal blood pressure dip 3. Total sleep time 4. Salt taste preference and sensitivity 5. Inflammatory markers 6. Optional: volumes of lateral ventricles, corpus callosum and choroid plexi. 7. Optional: white matter integrity, as measured by diffusion tensor imaging


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date March 2025
Est. primary completion date March 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Unipolar Depression - in women: Contraceptive means Exclusion Criteria: - Schizophrenic and delusional disorders - Neurological diseases in which central nervous system involvement is known, such as epilepsies, storage diseases; severe mental retardation - Internistic diseases of moderate or higher severity, which may make participation in the study risky from a clinical point of view. In particular, multiple systolic blood pressure (measured after at least 5 min supine position) of > 145 mm Hg as well as hypokalemia (< 3.5 mmol/l) and clinically relevant ECG changes - Poorly controlled diabetes mellitus (HbA1c > 10) - Pregnancy or active desire for pregnancy for the duration of the study - Non-consent or inability to consent to the study - Treatment with the following substances: spironolactone or eplerenone; systemic glucocorticoids - Treatment with ketamine or electroconvulsive therapy in the last 3 months before randomization - Acute suicidality - Intolerance to licorice preparations or licorice contents.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Enoxolone
one capsule of active or placebo in the evening

Locations

Country Name City State
Germany Clinic for Psychiatry and Psychotherapy Marburg Hessen

Sponsors (2)

Lead Sponsor Collaborator
Philipps University Marburg Medical Center Slovak Academy of Sciences

Country where clinical trial is conducted

Germany, 

References & Publications (5)

Engelmann J, Murck H, Wagner S, Zillich L, Streit F, Herzog DP, Braus DF, Tadic A, Lieb K, Muller MB. Routinely accessible parameters of mineralocorticoid receptor function, depression subtypes and response prediction: a post-hoc analysis from the early medication change trial in major depressive disorder. World J Biol Psychiatry. 2022 Oct;23(8):631-642. doi: 10.1080/15622975.2021.2020334. Epub 2022 Jan 25. — View Citation

Kubo Y, Kazui H, Yoshida T, Kito Y, Kimura N, Tokunaga H, Ogino A, Miyake H, Ishikawa M, Takeda M. Validation of grading scale for evaluating symptoms of idiopathic normal-pressure hydrocephalus. Dement Geriatr Cogn Disord. 2008;25(1):37-45. doi: 10.1159/000111149. Epub 2007 Nov 20. — View Citation

Murck H, Braunisch MC, Konrad C, Jezova D, Kircher T. Markers of mineralocorticoid receptor function: changes over time and relationship to response in patients with major depression. Int Clin Psychopharmacol. 2019 Jan;34(1):18-26. doi: 10.1097/YIC.0000000000000239. — View Citation

Murck H, Lehr L, Hahn J, Braunisch MC, Jezova D, Zavorotnyy M. Adjunct Therapy With Glycyrrhiza Glabra Rapidly Improves Outcome in Depression-A Pilot Study to Support 11-Beta-Hydroxysteroid Dehydrogenase Type 2 Inhibition as a New Target. Front Psychiatry. 2020 Dec 10;11:605949. doi: 10.3389/fpsyt.2020.605949. eCollection 2020. — View Citation

Murck H, Luerweg B, Hahn J, Braunisch M, Jezova D, Zavorotnyy M, Konrad C, Jansen A, Kircher T. Ventricular volume, white matter alterations and outcome of major depression and their relationship to endocrine parameters - A pilot study. World J Biol Psychiatry. 2021 Feb;22(2):104-118. doi: 10.1080/15622975.2020.1757754. Epub 2020 May 15. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Lateral cerebral ventricular volume Volume of lateral ventricles (sum) (mL), measured by MRI with freesurfer program change from baseline to 4 weeks
Other Corpus callosum volume Volume of corpus callosum (mL) segments, measured by MRI with freesurfer program change from baseline to 4 weeks
Other Choroid Plexus Volume Volume of Choroid Plexi (sum) (mL), measured by MRI with freesurfer program change from baseline to 4 weeks
Other Saliva aldosterone/cortisol ratio Ratio of saliva aldosterone concentration/saliva cortisol concentration change from baseline to 4 weeks
Primary Systolic blood pressure Systolic blood pressure at rest at baseline as a predictor for treatment differentiation Baseline, as predictor for differentiation of treatment groups clinical response
Primary Urine aldosterone/cortisol ratio Ratio of nocturnal urine aldosterone concentration/urine cortisol concentration Baseline, as predictor for differentiation of treatment groups clinical resposne
Primary Depression rating Hamilton depression rating scale (HAMD) - 17 items; higher is worse change from baseline to week 4, with systolic blood pressure as covariate
Primary Depression self rating Patient health questionnaire for depression (PHQ-9), higher is worse change from baseline to week 4, with systolic blood pressure as covariate
Secondary Systolic blood pressure Systolic blood pressure at rest change from baseline to week 4
Secondary Urine aldosterone/cortisol ratio Ratio of nocturnal urine aldosterone concentration/urine cortisol concentration change from baseline to week 4
Secondary Plasma ratio of sodium/potassium Ratio of the plasma concentration of sodium/ plasma concentration of potassium change from baseline to week 4
Secondary Nocturnal heart rate variability Average nocturnal heart rate variability, expressed as stress level (Garmin, arbitrary unit) change from baseline to week 4
Secondary Nocturnal blood pressure dip (difference between pre-sleep and minimal nocturnal blood pressure Minimum of continuously monitored systolic blood pressure (mmHg) change from baseline to week 4
Secondary Total sleep duration Total sleep duration, as determined by wearable device (Garmin) (minutes) change from baseline to week 4
Secondary Salt taste preference and sensitivity salt taste preference, as determined by tasting a 0.9% NaCl solution, 11 item Likert scale (Murck et al., 2018) change from baseline to week 4
Secondary Inflammation: C-reactive protein Plasma C-reactive protein concentration (mg/L) change from baseline to week 4
Secondary Rating for symptoms of normal pressure hydrocephalus Idiopathic normal pressure hydrocephalus grading scale (iNPHGS) (Kubo et al., 2008), higher is worse change from baseline to week 4
See also
  Status Clinical Trial Phase
Completed NCT03256162 - Ketamine as an Adjunctive Therapy for Major Depression Phase 1
Completed NCT02530164 - Transcranial Direct Current Stimulation (tDCS) As Treatment for Major Depression N/A
Completed NCT00964054 - Depression Outcomes Study of Exercise Phase 1
Completed NCT01447602 - A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior Phase 3
Completed NCT00517387 - The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression Phase 3
Recruiting NCT04939649 - Ketamine as an Adjunctive Therapy for Major Depression (2) Phase 3
Recruiting NCT05894980 - How to Reduce Suicidal Thoughts and Impulsivity in Depression N/A
Terminated NCT04712968 - Efficacy of Daylight as Adjunctive Treatment in Patients With Depression N/A
Enrolling by invitation NCT04717921 - Assesment of Retinal Nerve Fiber Layer in First Episode Depressive Patients Using Selective Serotonin Reuptake Inhibitor
Recruiting NCT03358056 - Effects of Mindfulness Based Cognitive Therapy on Emotional Processing N/A
Recruiting NCT03711019 - Efficacy of Convulsive Therapies During Continuation N/A
Completed NCT02104232 - Thinking Healthy Program - Peer Delivered, India (THPP-I) N/A
Completed NCT02111915 - Thinking Healthy Program - Peer Delivered (Pakistan) N/A
Terminated NCT01219686 - EScitalopram PIndolol ONset of Action Phase 2/Phase 3
Completed NCT00158990 - Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression. Phase 3
Completed NCT01049347 - Amitriptyline and Paroxetine Treatment of Major Depression Phase 3
Completed NCT03268434 - Evaluation of Metacognitive Training for Depression (D-MCT) in Outpatient Care N/A
Completed NCT01880957 - PET and MRI Brain Imaging of Bipolar Disorder N/A
Completed NCT04420793 - Voice Changes During ECT
Not yet recruiting NCT01694030 - Effects of Repeated Attachment Security Priming on Depressed Mood: a Clinical Study Phase 1